Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia
Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in patients with COVID-19 pneumonia. Pat...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167179/ https://www.ncbi.nlm.nih.gov/pubmed/34059708 http://dx.doi.org/10.1038/s41598-021-90713-6 |
_version_ | 1783701640223653888 |
---|---|
author | Vergori, Alessandra Lorenzini, Patrizia Cozzi-Lepri, Alessandro Donno, Davide Roberto Gualano, Gina Nicastri, Emanuele Iacomi, Fabio Marchioni, Luisa Campioni, Paolo Schininà, Vincenzo Cicalini, Stefania Agrati, Chiara Capobianchi, Maria Rosaria Girardi, Enrico Ippolito, Giuseppe Vaia, Francesco Petrosillo, Nicola Antinori, Andrea Taglietti, Fabrizio |
author_facet | Vergori, Alessandra Lorenzini, Patrizia Cozzi-Lepri, Alessandro Donno, Davide Roberto Gualano, Gina Nicastri, Emanuele Iacomi, Fabio Marchioni, Luisa Campioni, Paolo Schininà, Vincenzo Cicalini, Stefania Agrati, Chiara Capobianchi, Maria Rosaria Girardi, Enrico Ippolito, Giuseppe Vaia, Francesco Petrosillo, Nicola Antinori, Andrea Taglietti, Fabrizio |
author_sort | Vergori, Alessandra |
collection | PubMed |
description | Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in patients with COVID-19 pneumonia. Patients admitted to a COVID-hospital in Rome with SARS-CoV-2 infection and mild/moderate pneumonia were retrospectively evaluated. The primary endpoint was the time from hospital admission to orotracheal intubation/death (OTI/death). A total of 449 patients were included: 39% female, median age 63 (IQR, 50–77) years. The estimated probability of OTI/death for patients receiving pLMWH was: 9.5% (95% CI 3.2–26.4) by day 20 in those not receiving pLMWH vs. 10.4% (6.7–15.9) in those exposed to pLMWH; p-value = 0.144. This risk associated with the use of pLMWH appeared to vary by PaO(2)/FiO(2) ratio: aHR 1.40 (95% CI 0.51–3.79) for patients with an admission PaO(2)/FiO(2) ≤ 300 mmHg and 0.27 (0.03–2.18) for those with PaO(2)/FiO(2) > 300 mmHg; p-value at interaction test 0.16. pLMWH does not seem to reduce the risk of OTI/death mild/moderate COVID-19 pneumonia, especially when respiratory function had already significantly deteriorated. Data from clinical trials comparing the effect of prophylactic vs. therapeutic dosage of LMWH at various stages of COVID-19 disease are needed. |
format | Online Article Text |
id | pubmed-8167179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81671792021-06-02 Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia Vergori, Alessandra Lorenzini, Patrizia Cozzi-Lepri, Alessandro Donno, Davide Roberto Gualano, Gina Nicastri, Emanuele Iacomi, Fabio Marchioni, Luisa Campioni, Paolo Schininà, Vincenzo Cicalini, Stefania Agrati, Chiara Capobianchi, Maria Rosaria Girardi, Enrico Ippolito, Giuseppe Vaia, Francesco Petrosillo, Nicola Antinori, Andrea Taglietti, Fabrizio Sci Rep Article Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in patients with COVID-19 pneumonia. Patients admitted to a COVID-hospital in Rome with SARS-CoV-2 infection and mild/moderate pneumonia were retrospectively evaluated. The primary endpoint was the time from hospital admission to orotracheal intubation/death (OTI/death). A total of 449 patients were included: 39% female, median age 63 (IQR, 50–77) years. The estimated probability of OTI/death for patients receiving pLMWH was: 9.5% (95% CI 3.2–26.4) by day 20 in those not receiving pLMWH vs. 10.4% (6.7–15.9) in those exposed to pLMWH; p-value = 0.144. This risk associated with the use of pLMWH appeared to vary by PaO(2)/FiO(2) ratio: aHR 1.40 (95% CI 0.51–3.79) for patients with an admission PaO(2)/FiO(2) ≤ 300 mmHg and 0.27 (0.03–2.18) for those with PaO(2)/FiO(2) > 300 mmHg; p-value at interaction test 0.16. pLMWH does not seem to reduce the risk of OTI/death mild/moderate COVID-19 pneumonia, especially when respiratory function had already significantly deteriorated. Data from clinical trials comparing the effect of prophylactic vs. therapeutic dosage of LMWH at various stages of COVID-19 disease are needed. Nature Publishing Group UK 2021-05-31 /pmc/articles/PMC8167179/ /pubmed/34059708 http://dx.doi.org/10.1038/s41598-021-90713-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Vergori, Alessandra Lorenzini, Patrizia Cozzi-Lepri, Alessandro Donno, Davide Roberto Gualano, Gina Nicastri, Emanuele Iacomi, Fabio Marchioni, Luisa Campioni, Paolo Schininà, Vincenzo Cicalini, Stefania Agrati, Chiara Capobianchi, Maria Rosaria Girardi, Enrico Ippolito, Giuseppe Vaia, Francesco Petrosillo, Nicola Antinori, Andrea Taglietti, Fabrizio Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia |
title | Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia |
title_full | Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia |
title_fullStr | Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia |
title_full_unstemmed | Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia |
title_short | Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia |
title_sort | prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate covid-19 pneumonia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167179/ https://www.ncbi.nlm.nih.gov/pubmed/34059708 http://dx.doi.org/10.1038/s41598-021-90713-6 |
work_keys_str_mv | AT vergorialessandra prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT lorenzinipatrizia prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT cozzileprialessandro prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT donnodavideroberto prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT gualanogina prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT nicastriemanuele prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT iacomifabio prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT marchioniluisa prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT campionipaolo prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT schininavincenzo prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT cicalinistefania prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT agratichiara prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT capobianchimariarosaria prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT girardienrico prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT ippolitogiuseppe prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT vaiafrancesco prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT petrosillonicola prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT antinoriandrea prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT tagliettifabrizio prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia AT prophylacticheparinandriskoforotrachealintubationordeathinpatientswithmildormoderatecovid19pneumonia |